PARP Clinical Trials

1 recruiting

PARP Trials at a Glance

6 actively recruiting trials for parp are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Beijing, Boston, and Boulder. Lead sponsors running parp studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Dana-Farber Cancer Institute, and Ronald Buckanovich.

Browse parp trials by phase

Treatments under study

About PARP Clinical Trials

Looking for clinical trials for PARP? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PARP trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PARP clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Carcinoma+4 more
Dana-Farber Cancer Institute240 enrolled6 locationsNCT06710548
Recruiting
Phase 1Phase 2

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Advanced Solid TumorsPARP Inhibitor
Shanghai SciBrunch Therapeutics Co., Ltd.210 enrolled2 locationsNCT07359066
Recruiting
Phase 2

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP InhibitorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+1 more
Ronald Buckanovich48 enrolled1 locationNCT05538091
Recruiting
Phase 1Phase 2

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Breast CancerPancreatic CancerCancer+7 more
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.188 enrolled1 locationNCT06819215
Recruiting

Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University470 enrolled1 locationNCT06622798
Recruiting
Not Applicable

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

CDK4/6 InhibitorChemotherapeutic ToxicityTrastuzumab+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences148 enrolled1 locationNCT06197581